Supreme Court Says Government Can Challenge 'Pay For Delay' Generic Drug Deals
redOrbit Staff & Wire Reports - Your Universe Online Profit-sharing arrangements between generic and brand name drug companies that preserve patents and prevent competition are not inherently legal, and can be challenged as...
Latest Generic drug Stories
Controversial deals that delay generic versions of drugs coming onto the market can lead to consumers paying significantly more for some treatments, according to new research by an academic from the University of East Anglia. Dr Farasat Bokhari’s study shows that moves to investigate and ban pay-to-delay deals – which typically involve a branded manufacturer holding a drug patent paying a rival generic firm to delay the release of its cheaper version – are justified. The deals are on...
MUMBAI, India, June 19, 2013 /PRNewswire/ -- Bharat Book Bureau presents Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies (http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies.html ) There are more than 1400 sustained or...
MUMBAI, India, June 19, 2013 /PRNewswire/ -- Bharat Book Bureau has recently added DrugPatentWatch to its extensive list of Online Databases. (http://www.bharatbook.com/drugpatentwatch-tour.pdf) (Logo: http://photos.prnewswire.com/prnh/20130128/590935 ) DrugPatentWatch provides comprehensive information on pharmaceutical, drug patents and their expirations. This value-added information supports the critical business functions of patent agents and attorneys,...
SOMERSET, N.J., June 12, 2013 /PRNewswire/ -- GAVIS Pharmaceuticals, LLC announced today that it has launched My Way((TM)), Levonorgestrol 1.5 mg, the generic version of Teva Pharmaceutical's Plan B One Step(®) emergency contraceptive developed by Novel Laboratories, Inc. My Way((TM)) is available without a prescription to women age 17 years and older. (Photo: http://photos.prnewswire.com/prnh/20130612/NY31176 ) "GAVIS is committed to bringing quality and affordable drug products...
DUBLIN, June 11, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/hrlbkd/top_five_global) has announced the addition of the "Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis" [http://www.researchandmarkets.com/research/hrlbkd/top_five_global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The fragmented market has observed some changes in the...
In response to client requests, Integral BioSystems is developing and will be licensing Integral’s novel platform ophthalmic formulation technologies for use in treatment of disease in both the front and the back of the eye. Bedford, MA (PRWEB) May 28, 2013 Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., is developing and will offer for license its novel, platform front-of-the-eye and back-of-the-eye ophthalmic therapeutic...
Lucintel profiles leaders in generic drugs industry: global market expected to reach US $335.8 Billion in 2017 Irving, TX (PRWEB) May 14, 2013 Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over the last five years and is expected to reach approximately US $335.8 billion in 2017. Lucintel,...
Stein Mitchell Muse & Cipollone LLP Announces Largest Generic Drug Whistleblower Settlement in History WASHINGTON, May 13, 2013 /PRNewswire-USNewswire/ -- Stein Mitchell Muse & Cipollone LLP announced today that Ranbaxy Laboratories Limited ("Ranbaxy"), India's largest generic drug manufacturer, has agreed to pay $500 million to the United States and individual States to resolve allegations by the law firm's client, Dinesh S. Thakur, that Ranbaxy falsified drug data and...
WASHINGTON, May 13, 2013 /PRNewswire-USNewswire/ -- Today, the United States government brought to a conclusion an eight-year criminal and civil investigation of Ranbaxy Laboratories Limited, India's largest generic drug company, and Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy Laboratories, Inc., Ranbaxy USA, Inc., and Ohm Laboratories, Inc. ("Ranbaxy"). Ranbaxy has agreed to pay $500 million to resolve allegations of falsifying drug data and systemic manufacturing...
“Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan” is the new market research report added to ReportsnReports.com store. Dallas, TX (PRWEB) May 09, 2013 Keep current with the changing CIS generic and innovative drug segments. Survey conditions and track market development in Russian Ukraine and Kazakhstan to 2015. Generic and innovative drug segments in CIS countries have played a huge role in supporting the pharmaceutical industry. Meanwhile,...
